IMMUNITYBIO, INC. (IBRX) Gross margin 2022–2025
IMMUNITYBIO, INC. (IBRX) gross margin by fiscal year — reported gross profit divided by reported revenue.
99.3%FY2025 · since FY2022: 100.0% → 99.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 99.3% | -0.7 pp |
| FY2024 | 100.0% | +0.0 pp |
| FY2023 | 100.0% | +0.0 pp |
| FY2022 | 100.0% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More IBRX financial trends
IBRX RevenueIBRX Net incomeIBRX Net marginIBRX Gross profitIBRX Operating incomeIBRX Operating marginIBRX Operating cash flowIBRX Free cash flowIBRX Capital expendituresIBRX Return on equityIBRX Stock buybacksIBRX Dividends paidIBRX Total assetsIBRX Total liabilitiesIBRX Shareholders’ equityIBRX overview →